{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T12:46:52Z","timestamp":1754398012776,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T00:00:00Z","timestamp":1440720000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s12032-015-0682-z","type":"journal-article","created":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T14:34:13Z","timestamp":1440686053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia"],"prefix":"10.1007","volume":"32","author":[{"given":"Gilles","family":"Freyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Kalinka-Warzocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Syrigos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihai","family":"Marinca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Tonini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Say Liang","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zee Wan","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Salar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guenther","family":"Steger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Abdelsalam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"DeCosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,28]]},"reference":[{"issue":"Suppl 4","key":"682_CR1","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1086\/427329","volume":"40","author":"C Viscoli","year":"2005","unstructured":"Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis. 2005;40(Suppl 4):S240\u20135.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 5","key":"682_CR2","doi-asserted-by":"crossref","first-page":"v252","DOI":"10.1093\/annonc\/mdq196","volume":"21","author":"J Naurois de","year":"2010","unstructured":"de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21(Suppl 5):v252\u20136.","journal-title":"Ann Oncol"},{"key":"682_CR3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/sj.bjc.6606059","volume":"104","author":"M Okera","year":"2011","unstructured":"Okera M, Chan S, Dernede U, Larkin J, Popat S, Gilbert D, et al. A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG\/NCEPOD findings. Br J Cancer. 2011;104:407\u201312.","journal-title":"Br J Cancer"},{"key":"682_CR4","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1093\/annonc\/mdr520","volume":"23","author":"S Schelenz","year":"2012","unstructured":"Schelenz S, Giles D, Abdallah S. Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre. Ann Oncol. 2012;23:1889\u201393.","journal-title":"Ann Oncol"},{"key":"682_CR5","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258\u201366.","journal-title":"Cancer"},{"key":"682_CR6","first-page":"19","volume":"17","author":"S Khan","year":"2008","unstructured":"Khan S, Dhadda A, Fyfe D, Sundar S. Impact of neutropenia on delivering planned chemotherapy for solid tumours. Eur J Cancer Care (Engl). 2008;17:19\u201325.","journal-title":"Eur J Cancer Care (Engl)"},{"key":"682_CR7","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood.V80.6.1430.1430","volume":"80","author":"R Pettengell","year":"1992","unstructured":"Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wilkinson PM, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin\u2019s lymphoma: a randomized controlled trial. Blood. 1992;80:1430\u20136.","journal-title":"Blood"},{"key":"682_CR8","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00520-008-0430-4","volume":"16","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, Schwenkglenks M, Leonard R, Bosly A, Paridaens R, Constenla M, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer. 2008;16:1299\u2013309.","journal-title":"Support Care Cancer"},{"key":"682_CR9","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/jnci\/90.16.1205","volume":"90","author":"DR Budman","year":"1998","unstructured":"Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90:1205\u201311.","journal-title":"J Natl Cancer Inst"},{"key":"682_CR10","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.2001.19.3.602","volume":"19","author":"French Adjuvant Study Group","year":"2001","unstructured":"French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol. 2001;19:602\u201311.","journal-title":"J Clin Oncol"},{"key":"682_CR11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.critrevonc.2010.02.002","volume":"77","author":"H Wildiers","year":"2011","unstructured":"Wildiers H, Reiser M. Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol. 2011;77:221\u201340.","journal-title":"Crit Rev Oncol Hematol"},{"key":"682_CR12","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11:404.","journal-title":"BMC Cancer"},{"key":"682_CR13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","volume":"325","author":"J Crawford","year":"1991","unstructured":"Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164\u201370.","journal-title":"N Engl J Med"},{"key":"682_CR14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00520-014-2457-z","volume":"23","author":"AM Pfeil","year":"2014","unstructured":"Pfeil AM, Allcott K, Pettengell R, von Minckwitz G, Schwenkglenks M, Szabo Z. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer. 2014;23:525\u201345.","journal-title":"Support Care Cancer"},{"key":"682_CR15","doi-asserted-by":"crossref","first-page":"LBA445","DOI":"10.1200\/jco.2013.31.4_suppl.lba445","volume":"30","author":"T Pinter","year":"2013","unstructured":"Pinter T, Abella S, Cesas A, Croitoru A, Decaestecker J, Gibbs P, et al. Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC). J Clin Oncol. 2013;30:LBA445.","journal-title":"J Clin Oncol"},{"key":"682_CR16","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178\u201384.","journal-title":"J Clin Oncol"},{"key":"682_CR17","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158\u201367.","journal-title":"J Clin Oncol"},{"key":"682_CR18","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ejca.2008.11.021","volume":"45","author":"G Minckwitz von","year":"2009","unstructured":"von Minckwitz G, Schwenkglenks M, Skacel T, Lyman GH, Pousa AL, Bacon P, et al. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. Eur J Cancer. 2009;45:608\u201317.","journal-title":"Eur J Cancer"},{"key":"682_CR19","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","volume":"24","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013;24:2475\u201384.","journal-title":"Ann Oncol"},{"issue":"47","key":"682_CR20","first-page":"8","volume":"2011","author":"MS Aapro","year":"2010","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2010;2011(47):8\u201332.","journal-title":"Eur J Cancer"},{"issue":"Suppl 5","key":"682_CR21","doi-asserted-by":"crossref","first-page":"v248","DOI":"10.1093\/annonc\/mdq195","volume":"21","author":"J Crawford","year":"2010","unstructured":"Crawford J, Caserta C, Roila F. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol. 2010;21(Suppl 5):v248\u201351.","journal-title":"Ann Oncol"},{"unstructured":"National Comprehensive Cancer Network. 2006 Update of ASCO practice guideline recommendations for the use of white blood cell growth factors: guideline summary V.1.2010. NCCN Clinical Practice Guidelines in Oncology. 2010. http:\/\/jhasioncology.com\/fn2010\/eresourcecenter\/pdfs\/NCCN%20myeloid_growth%20factor%20guidelines.%20v1.2010.pdf . Accessed 30 Jan 2015.","key":"682_CR22"},{"unstructured":"National Comprehensive Cancer Network. Prevention and treatment of cancer-related infections V.1.2013. NCCN Clinical Practice Guidelines in Oncology. 2013. http:\/\/oralcancerfoundation.org\/treatment\/pdf\/infections.pdf . Accessed 30 Jan 2015.","key":"682_CR23"},{"key":"682_CR24","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","volume":"10","author":"GH Lyman","year":"2005","unstructured":"Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005;10:427\u201337.","journal-title":"Oncologist"},{"key":"682_CR25","first-page":"273","volume":"11","author":"A Jha","year":"2013","unstructured":"Jha A. Spectrum of hematological malignancies and peripheral cytopenias. J Nepal Health Res Counc. 2013;11:273\u20138.","journal-title":"J Nepal Health Res Counc"},{"unstructured":"National Cancer Institute. SEER cancer statistics review 1975\u20132003. http:\/\/seer.cancer.gov\/archive\/csr\/1975_2003\/results_single\/sect_01_table.11_2pgs.pdf . Accessed 30 Jan 2015.","key":"682_CR26"},{"key":"682_CR27","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351.","journal-title":"Blood"},{"key":"682_CR28","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.ejca.2010.04.031","volume":"46","author":"C Falandry","year":"2010","unstructured":"Falandry C, Campone M, Cartron G, Guerin D, Freyer G. Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. Eur J Cancer. 2010;46:2389\u201398.","journal-title":"Eur J Cancer"},{"key":"682_CR29","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.critrevonc.2011.03.003","volume":"81","author":"A Chan","year":"2012","unstructured":"Chan A, Verma S, Loibl S, Crawford J, Choi MR, Dreiling L, et al. Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. Crit Rev Oncol Hematol. 2012;81:136\u201350.","journal-title":"Crit Rev Oncol Hematol"},{"key":"682_CR30","doi-asserted-by":"crossref","first-page":"440","DOI":"10.6004\/jnccn.2003.0038","volume":"1","author":"DC Dale","year":"2003","unstructured":"Dale DC, McCarter GC, Crawford J, Lyman GH. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw. 2003;1:440\u201354.","journal-title":"J Natl Compr Canc Netw"},{"key":"682_CR31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1548-5315(12)70028-1","volume":"8","author":"SAAS Gregory","year":"2011","unstructured":"Gregory SAAS, Moore T. Underreporting of neutropenic toxicity associated with current treatment regimens for selected hematologic malignancies. Commun Oncol. 2011;8:311\u201325.","journal-title":"Commun Oncol"},{"key":"682_CR32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3747\/co.v18i3.751","volume":"18","author":"Y Madarnas","year":"2011","unstructured":"Madarnas Y, Dent SF, Husain SF, Robinson A, Alkhayyat S, Hopman WM, et al. Real-world experience with adjuvant FEC-D chemotherapy in four Ontario regional cancer centres. Curr Oncol. 2011;18:119\u201325.","journal-title":"Curr Oncol"},{"key":"682_CR33","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s00520-011-1375-6","volume":"20","author":"T Younis","year":"2012","unstructured":"Younis T, Rayson D, Thompson K. Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis. Support Care Cancer. 2012;20:2523\u201330.","journal-title":"Support Care Cancer"},{"key":"682_CR34","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejon.2013.11.002","volume":"18","author":"C O\u2019Brien","year":"2014","unstructured":"O\u2019Brien C, Dempsey O, Kennedy MJ. Febrile neutropenia risk assessment tool: improving clinical outcomes for oncology patients. Eur J Oncol Nurs. 2014;18:167\u201374.","journal-title":"Eur J Oncol Nurs"},{"key":"682_CR35","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1200\/JOP.2012.000810","volume":"9","author":"KL Vavra","year":"2013","unstructured":"Vavra KL, Saadeh CE, Rosen AL, Uptigrove CE, Srkalovic G. Improving the relative dose intensity of systemic chemotherapy in a community-based outpatient cancer center. J Oncol Pract. 2013;9:e203\u201311.","journal-title":"J Oncol Pract"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-015-0682-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-015-0682-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-015-0682-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:49:00Z","timestamp":1653094140000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-015-0682-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,28]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["682"],"URL":"https:\/\/doi.org\/10.1007\/s12032-015-0682-z","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"type":"print","value":"1357-0560"},{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2015,8,28]]},"article-number":"236"}}